1332 Anti-CD161 antibody IMT-009 is a novel immunotherapeutic agent that reinvigorates T and NK cell function and anti-tumor efficacy through blocking interaction of CD161 with its ligand CLEC2D

Fusco, A; Scanlon, Elizabeth; Irvine, Frano; Brown, Flavian D.; Colbert, J.; Tu, Andy; Gaerlan, Stephanie C.; Nichols, Kelly K.; Rham, Teresse de; Huggins, Matthew A; Dionne, Kendall; Tang, Ming; Flick, Heather; Tisdale, Alison W.; Tan, Seng‐Lai; Malu, Shruti

doi:10.1136/jitc-2022-sitc2022.1332

Regular and Young Investigator Award Abstracts 2022

DOI: 10.1136/jitc-2022-sitc2022.1332

|View full text |Cite

1332 Anti-CD161 antibody IMT-009 is a novel immunotherapeutic agent that reinvigorates T and NK cell function and anti-tumor efficacy through blocking interaction of CD161 with its ligand CLEC2D

A Fusco

Elizabeth Scanlon

Frano Irvine

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Publication Types

Select...

Relationship

Self Cite0

Independent0

Authors

Journals

Cited by 0 publications

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

No citations

Set email alert for when this publication receives citations?

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

1332 Anti-CD161 antibody IMT-009 is a novel immunotherapeutic agent that reinvigorates T and NK cell function and anti-tumor efficacy through blocking interaction of CD161 with its ligand CLEC2D

Cited by 0 publications

References 1 publication

No citations

Contact Info

Product

Resources

About